EU firms facing new requirements for orphan drug designation
This article was originally published in Scrip
Executive Summary
Companies developing products for rare diseases in the EU could be facing changes to the requirements for gaining orphan drug designation, after the European Commission announced that it planned to review the criteria for showing that a new product has a "significant benefit" over existing treatments.